Skip to main content
Clinical Trials/NCT05817032
NCT05817032
Recruiting
Not Applicable

Effect of Telerehabilitation Practice in Long COVID-19 Patients: Impact on Stress Oxidative, Inflammation, Functional Capacity and Quality of Life

Indonesia University1 site in 1 country22 target enrollmentMay 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Long COVID-19
Sponsor
Indonesia University
Enrollment
22
Locations
1
Primary Endpoint
Change from baseline the mean Glutathione (GSH)/ oxidized GSH (GSSG) ratio at 12 weeks
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The goal of this clinical trial is to test the efficacy of telerehabilitation practice in Long COVID-19 patients. The main question[s] it aims to answer are whether telerehabilitation practice in Long COVID-19 patients help to reduce stress oxidative, reduce inflammation, improve functional capacity and improve quality of life.

Participants will receive 12 weeks of telerehabilitation practice Researchers will compare intervention group (that received telerehabilitation) and control group (that received standard treatment) to see if there is better outcome in intervention group.

Detailed Description

Study background: Several study show that some survivors of COVID-19 have post COVID-19 sequelae. Previous studies suggest that rehabilitation interventions with appropriate prescription of physical exercise can provide short, medium and long term health benefits. Telerehabilitation services are an innovative strategy to support rehabilitation intervention and hopefully able to increase compliance of patients to exercise program. This study aims to prove the effectiveness of telerehabilitation in improving levels of inflammation, oxidative stress, functional capacity and quality of life in Long COVID-19 patients. Participants will be divided into intervention group and control group. Baseline measurement will be taken. Telerehabilitation will be given to the intervention group for 12 weeks. Control group will receive standard rehabilitation treatment. After 12 weeks post intervention measurement will be taken.

Registry
clinicaltrials.gov
Start Date
May 2023
End Date
November 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nurul Paramita

dr, M.Biomed, SpKFR

Indonesia University

Eligibility Criteria

Inclusion Criteria

  • COVID-19 survivors
  • Have at least one of the following sequelae:
  • dyspnea and/or chronic cough
  • joint and/or muscle pain
  • insomnia (difficulty sleeping)
  • impaired concentration / memory
  • Willing to take part in the telerehabilitation program regularly during the study
  • Willing to participate in the research and sign the consent form

Exclusion Criteria

  • Unable to use the mobile phone application and zoom meet
  • Unable to come to the hospital for examination or training (if needed)
  • Cognitive impairment (MMSE \<21)
  • Neuromusculoskeletal disorder which will affect rehabilitation interventions
  • Severe chronic lung disease
  • Severe heart disease (Grade III-IV from the New York Heart Association)
  • Chronic kidney disorders
  • Malignancy
  • Severe autoimmune disease

Outcomes

Primary Outcomes

Change from baseline the mean Glutathione (GSH)/ oxidized GSH (GSSG) ratio at 12 weeks

Time Frame: Baseline and week 12

The ratio of reduced Glutathione (GSH) to oxidized GSH (GSSG) is an indicator of cellular health, with reduced GSH constituting up to 98% of cellular GSH under normal conditions. It will be measured using The Glutathione GSH/GSSG Assay Kit, which is designed to accurately measure total, reduced and oxidized glutathione in biological samples using an enzymatic method that utilizes Ellman's Reagent (DTNB) and glutathione reductase (GR).

Change from baseline the mean endothelial microparticles at 12 weeks

Time Frame: Baseline and week 12

Endothelial microparticles is an emerging marker of endothelial dysfunction and also considered to play a major biological role in inflammation, vascular injury, angiogenesis, and thrombosis. Techniques to measure circulating endothelial microparticles rely on differential centrifugation in platelet-free plasma and on the identification of cell-surface Cluster of Differentiations (CD) antigens.

Change from baseline in quality of life status measured using European Quality of Life 5 Dimension 5 Level (EQ 5D 5L) questionnaire at 12 weeks

Time Frame: Baseline and week 12

European Quality of Life 5 Dimension 5 Level (EQ 5D 5L) questionnaire is a validated instrument to measure quality of life. It is a descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

Change from baseline the distance from Six Minute Walk Test at 12 weeks

Time Frame: Baseline and week 12

Six minute walk test is a validated instrument developed by the American Thoracic Society and it was officially introduced in 2002, coming along with a comprehensive guideline. The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

Secondary Outcomes

  • Change from baseline the score from hand grip strength test using handgrip dynamometer at 12 weeks(Baseline and 12 weeks)
  • Change from baseline the score from Brief Fatigue Inventory (BFI) questionnaire at 12 weeks(Baseline and 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials